The use of a cannabis spray as part of the treatment plan for certain patients with cancer is taking another step forward with the announcement of continued clinical research by the New South Wales-based Medlab Clinical LTD.
The phase I study is being led by Professor Stephen Clarke and has reached the second stage of the research.
The safety, tolerability and exploratory end-point pilot study is assessing the administration of a cannabis extract as an adjunct to opioid analgesia for the management of intractable pain in patients with advanced cancer.
Patients are being dosed with the extract using a buccal spray delivery system.
Recruitment of patients has already taken place and study participants have progressed through stage I — recruitment and dosing of the patients with standard dosings of 2.6 milligrams of tetrahydrocannabinol (THC) and 2.4 milligrams of cannabidiol (CBD) in 0.3 millilitres, up to three times a day.
Video report from Proactive Investors:
The THC-CBD therapeutic is part of the NanaBis program Medlab hopes to eventually present for registration as a drug rather than a medicinal product.
Under the program, the NanaBis product has a 1:1 ratio of CBD:THC and NanaBidial has a 18:2 ratio of CBD:THC.
The products are available to Australian patients through a compassionate use allowance that was authorised by the Federal Government through its Special Access Scheme (SAS).
Read full story.